Paper3535593
Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages.
Crowle AJ and 2 others. Am Rev Respir Dis, 1986. Cited by 51 papers, by iCite.
Cite this record
ConductScience Library. Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages. Papers, record 3535593. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3535593
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Macrophages | Major topic |
| Mycobacterium | Major topic |
| Nontuberculous Mycobacteria | Major topic |
| Pyrazinamide | Major topic |
| Adult | |
| Bacteriological Techniques | |
| Cells, Cultured | |
| Dose-Response Relationship, Drug | |
| Humans | |
| Middle Aged | |
| Osmolar Concentration | |
| Time Factors |
Source PubMed
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 51 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39240337 | Therapeutic drug monitoring in tuberculosis. | Eur J Clin Pharmacol | 2024 | https://conductscience.org/library/papers/39240337 | PubMed |
| 38071218 | Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide. | Nat Commun | 2023 | https://conductscience.org/library/papers/38071218 | PubMed |
| 31669220 | Impact of the host environment on the antitubercular action of pyrazinamide. | EBioMedicine | 2019 | https://conductscience.org/library/papers/31669220 | PubMed |
| 26967493 | The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB. | PLoS Comput Biol | 2016 | https://conductscience.org/library/papers/26967493 | PubMed |
| 25348525 | High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/25348525 | PubMed |
| 22470120 | Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2012 | https://conductscience.org/library/papers/22470120 | PubMed |
| 20156156 | Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. | Curr Clin Pharmacol | 2010 | https://conductscience.org/library/papers/20156156 | PubMed |
| 15673774 | Simple fibroblast-based assay to test the pyrazinamide susceptibility of Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/15673774 | PubMed |
| 12121929 | Simple fibroblast-based assay for screening of new antimicrobial drugs against Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/12121929 | PubMed |
| 11914348 | Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. | J Bacteriol | 2002 | https://conductscience.org/library/papers/11914348 | PubMed |
| 10796561 | Fully intermittent dosing with drugs for tuberculosis. | Cochrane Database Syst Rev | 2000 | https://conductscience.org/library/papers/10796561 | PubMed |
| 10496301 | Pharmacokinetic factors in the modern drug treatment of tuberculosis. | Clin Pharmacokinet | 1999 | https://conductscience.org/library/papers/10496301 | PubMed |
| 10348747 | Intrapulmonary concentrations of pyrazinamide. | Antimicrob Agents Chemother | 1999 | https://conductscience.org/library/papers/10348747 | PubMed |
| 9784514 | Differential growth characteristics and streptomycin susceptibility of virulent and avirulent Mycobacterium tuberculosis strains in a novel fibroblast-mycobacterium microcolony assay. | Infect Immun | 1998 | https://conductscience.org/library/papers/9784514 | PubMed |
| 9303411 | Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9303411 | PubMed |
| 3129990 | Pyrazinamide is not effective against intracellularly growing Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 1988 | https://conductscience.org/library/papers/3129990 | PubMed |
| 3126704 | Radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis in egg-yolk-enriched BACTEC 12A medium. | Antimicrob Agents Chemother | 1988 | https://conductscience.org/library/papers/3126704 | PubMed |
| 2802553 | Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254. | Antimicrob Agents Chemother | 1989 | https://conductscience.org/library/papers/2802553 | PubMed |
| 2492972 | Inhibition by retinoic acid of multiplication of virulent tubercle bacilli in cultured human macrophages. | Infect Immun | 1989 | https://conductscience.org/library/papers/2492972 | PubMed |
| 2127346 | Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3. | Antimicrob Agents Chemother | 1990 | https://conductscience.org/library/papers/2127346 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3535593
GET https://conductscience.org/api/papers/v1/3535593/cited_by?page=2